<DOC>
	<DOCNO>NCT00392327</DOCNO>
	<brief_summary>This randomized phase III trial study different chemotherapy radiation therapy regimens compare well work treat young patient newly diagnose , previously untreated , high-risk medulloblastoma . Drugs use chemotherapy , vincristine sulfate , cisplatin , cyclophosphamide , carboplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving one drug ( combination chemotherapy ) may kill tumor cell . Isotretinoin may help chemotherapy work well make tumor cell sensitive drug . Radiation therapy use high-energy x-ray kill tumor cell . Carboplatin may make tumor cell sensitive radiation therapy . It yet know chemotherapy radiation therapy regimen effective treat brain tumor .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Treating Young Patients With Newly Diagnosed , Previously Untreated , High-Risk Medulloblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether carboplatin radiosensitization increase long term event-free survival high risk medulloblastoma/primitive neuroectodermal tumor ( PNET ) patient . II . To determine whether isotretinoin increase long term event-free survival high risk medulloblastoma/PNET patient . SECONDARY OBJECTIVES : I . To compare residual disease response radiation alone versus radiation plus carboplatin . II . To identify molecular prognostic indicator suitable patient stratification future trial . III . To evaluate health-related quality life ( HRQOL ) phase active treatment specific treatment modality . IV . To describe neuropsychological functioning study population evaluate relationship neuropsychological status health relate quality life . OUTLINE : Patients randomize 1 4 treatment arm . ARM I ( standard chemoradiotherapy standard maintenance therapy ) : CHEMORADIOTHERAPY : Patients undergo radiation therapy daily ( QD ) five day week 6 week . Patients also receive vincristine sulfate intravenously ( IV ) 1 minute weekly 6 week . Six week completion chemoradiotherapy , patient proceed maintenance therapy . MAINTENANCE THERAPY : Patients receive cisplatin IV 6 hour day 1 , vincristine sulfate IV 1 minute day 1 8 , cyclophosphamide IV 1 hour day 2 3 . Patients also receive filgrastim subcutaneously ( SC ) IV begin day 4 continue blood count recover ( least 10 day ) . Treatment repeat every 28 day total 6 course absence disease progression unacceptable toxicity . ARM II ( standard chemoradiotherapy plus carboplatin standard maintenance therapy ) : CHEMORADIOTHERAPY : Patients receive vincristine sulfate undergo radiation therapy Arm I . Patients also receive carboplatin IV 15 minute day radiation therapy . Six week completion chemoradiotherapy , patient proceed maintenance therapy . MAINTENANCE THERAPY : Patients receive maintenance therapy Arm I . ARM III ( standard chemoradiotherapy , standard maintenance therapy plus isotretinoin , continuation therapy isotretinoin ) : CHEMORADIOTHERAPY : Patients undergo chemoradiotherapy Arm I . Six week completion chemoradiotherapy , patient proceed maintenance therapy . MAINTENANCE THERAPY : Patients receive isotretinoin orally ( PO ) twice daily ( BID ) day 1 day 16-28 cisplatin , vincristine sulfate , cyclophosphamide , filgrastim Arm I maintenance therapy . Treatment repeat every 28 day total 6 course absence disease progression unacceptable toxicity . Patients proceed continuation therapy . CONTINUATION THERAPY : Patients receive isotretinoin PO BID day 15-28 every 28 day 6 course absence disease progression unacceptable toxicity . ARM IV ( standard chemoradiotherapy plus carboplatin , standard maintenance therapy plus isotretinoin , continuation therapy isotretinoin ) : CHEMORADIOTHERAPY : Patients undergo chemoradiotherapy Arm II . Six week completion chemoradiotherapy , patient proceed maintenance therapy . MAINTENANCE THERAPY : Patients receive maintenance therapy Arm III . Patients proceed continuation therapy . CONTINUATION THERAPY : Patients receive continuation therapy Arm III . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Newly diagnose , previously untreated : ( 1 ) M0 medulloblastoma &gt; 1.5 cm^2 residual ; ( 2 ) M+ medulloblastoma ; patient diffusely anaplastic medulloblastoma eligible regardless Mstage residual tumor As amendment # 2 , enrollment patient supratentorial PNET discontinue All patient M4 disease eligible A preoperative magnetic resonance imaging ( MRI ) scan brain without contrast require ; NOTE : compute tomography ( CT ) scan NOT sufficient study eligibility Postoperative head MRI scan without contrast ( preferably within 72 hour postsurgery ) ; patient undergo stereotactic biopsy , either pre postoperative MRI sufficient ; patient M2 M3 disease , postop MRI strongly encourage , mandatory Spinal MRI image without gadolinium require within 10 day surgery do preoperatively within 28 day surgery do postoperatively ; posterior fossa tumor , preoperative MRI scan prefer Lumbar cerebrospinal fluid ( CSF ) cytology examination must obtain preoperatively within 31 day follow surgery ; optimal time obtain CSF prior surgery 13 week follow surgery ; ventricular CSF ( either pre postop ) may use postoperative spinal tap contraindicate ; spinal tap contraindicate ventricular CSF available , CSF cytology waive patient supratentorial tumor documentation spinal subarachnoid metastasis ( M3 ) ; patient categorize M1 must either intraoperative positive CSF ( via lumbar puncture end procedure ) positive lumbar CSF obtain &gt; 7 day postoperatively Patients must Karnofsky performance level &gt; = 30 patient &gt; 16 year age Lansky performance scale &gt; = 30 patient = &lt; 16 year age life expectancy &gt; 8 week No previous chemotherapy radiation therapy Patients take Accutane ( isotretinoin ) acne must discontinue drug use indication prior enrollment ; corticosteroid use chemotherapy administration antiemetic Isotretinoin contraindicate patient parabens allergy patient soybean allergy ; concurrent use tetracycline avoid ; intake vitamin A limited duration isotretinoin treatment Selected strong inhibitor cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( cytochrome P450 3A4 ) include azole antifungal , fluconazole , voriconazole , itraconazole , ketoconazole , strong inducer include drug rifampin , phenytoin , phenobarbitol , carbamazepine , St. John 's wort ; use drug avoid vincristine ( vincristine sulfate ) CYP450 3A4 stimulators inhibitor avoid used great caution take cyclophosphamide ; aprepitant also use caution etoposide vincristine chemotherapy Cisplatin use caution nephrotoxic drug ; aminoglycoside avoid use caution shortly cisplatin administration concomitant use amphotericin B probably also avoid ; patient receive cisplatin potentially ototoxic drug aminoglycoside loop diuretic concomitantly closely monitored sign ototoxicity Plasma level anticonvulsant agent monitor dos adjust therapy cisplatin No experimental therapy permit study Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 OR serum creatinine base age/gender follow : 0.4 mg/dL ( 1 month &lt; 6 month age ) 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 &lt; 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( &gt; = 16 year age ) Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 2.5 x upper limit normal ( ULN ) age ; patient antiseizure medication , SGOT ( AST ) SGPT ( ALT ) must &lt; 5 x ULN Absolute neutrophil count ( ANC ) &gt; = 1,000/uL Platelets &gt; = 100,000/uL ( untransfused ) Hemoglobin &gt; = 8 g/dl ( may transfuse ) Female patient postmenarchal must negative pregnancy test ; lactate female patient must agree breastfeed trial ; male female reproductive potential may participate unless agree use effective contraceptive method All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>